Skip to main content
  • Home
  • Healthcare
  • “From Drug Development to Production”: Global Big Pharma Expands Investment in China, Accelerating Its Rise as a Biotech and Pharmaceutical Powerhouse

“From Drug Development to Production”: Global Big Pharma Expands Investment in China, Accelerating Its Rise as a Biotech and Pharmaceutical Powerhouse

Picture

Member for

2 years
Real name
Tyler Hansbrough
Bio
[email protected]

As one of the youngest members of the team, Tyler Hansbrough is a rising star in financial journalism. His fresh perspective and analytical approach bring a modern edge to business reporting. Whether he’s covering stock market trends or dissecting corporate earnings, his sharp insights resonate with the new generation of investors.

Modified

Eli Lilly expands joint drug development and technology licensing with Chinese biotech companies
Investment boom in “China biotech” spreads across global Big Pharma
Chinese government strengthens institutional support to accelerate pharmaceutical and biotech industry development

U.S. pharmaceutical company Eli Lilly is expanding its investment in China's biotech market. Alongside committing substantial funds to expanding local manufacturing facilities and supply chains, it is stepping up joint drug development with local biotech companies and efforts to secure next-generation technologies. This push to increase investment in China extends beyond Eli Lilly to global Big Pharma more broadly, while the Chinese government is strengthening policy support to foster its pharmaceutical and biotech industries.

China's METiS TechBio Joins Forces with Eli Lilly

According to Reuters on the 19th local time, Hong Kong-listed Chinese biotech company METiS TechBio announced that it had signed a joint research and development (R&D) agreement with Eli Lilly for tissue-specific drug delivery technology. The collaboration centers on securing next-generation drug delivery technology that uses lipid nanoparticles (LNPs) to deliver therapeutic substances more precisely to specific tissues. METiS TechBio plans to develop new drug delivery materials and technologies through AiLNP, its artificial intelligence (AI)-based platform for discovering and optimizing ionizable lipids. Ionizable lipids are a key component of LNPs, helping securely encapsulate therapeutic substances within the particles and deliver them into cells.

Eli Lilly will contribute expertise in drug candidate discovery, clinical development and commercialization, and will make payments to METiS TechBio under the agreement. It will initially pay tens of millions of USD upfront, followed by up to USD 1.1 billion (approximately USD 1.12 billion) in additional milestone payments tied to development, regulatory approval and commercialization targets. Separately, METiS TechBio may also receive tiered royalties at single-digit percentages of annual net sales if products developed through the joint research are commercialized.

Building a Manufacturing Network for Obesity and Diabetes Treatments

This is not Eli Lilly's first major investment initiative in China. In March, Eli Lilly announced plans to invest USD 3 billion (approximately USD 3.06 billion) in China over the next 10 years to expand local pharmaceutical manufacturing facilities and supply chains. The investment centers on expanding production capacity for orforglipron, an oral treatment for obesity and diabetes. Orforglipron is a once-daily, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Late last year, Eli Lilly applied to China's National Medical Products Administration (NMPA) for marketing approval for the treatment's use in obesity and type 2 diabetes.

Eli Lilly's investment will be used to upgrade its existing manufacturing facilities in Suzhou, China, and establish a new oral solid dosage manufacturing facility in Beijing. It will also build a large-scale pharmaceutical production system through partnerships with local contract development and manufacturing organizations (CDMOs). Eli Lilly has signed a collaboration agreement with Beijing-based pharmaceutical CDMO Pharmaron and committed USD 200 million (approximately USD 204 million) to expand manufacturing technology and facility capabilities. Pharmaron plans to use the funds to establish the technological foundation needed to manufacture next-generation oral treatments, including orforglipron, and gradually scale up production in line with future demand.

Partnering with Chinese Companies on Drug Development

In May, Eli Lilly also signed a joint drug R&D and licensing agreement with China's Haisco Pharmaceutical Group. According to U.S. pharmaceutical industry publication Fierce Biotech, the collaboration covers up to 5 new drug target discovery and development programs, aiming to develop innovative medicines across multiple disease areas. Haisco will handle candidate discovery and early-stage research for targets selected by Eli Lilly, while Eli Lilly will lead subsequent development, from the nonclinical studies needed for investigational new drug (IND) applications through clinical trials, regulatory approval and commercialization. Specific disease areas and drug candidates were not disclosed.

Under the agreement, Haisco will receive up to USD 87 million (approximately USD 88.5 million) in upfront and near-term payments, and may receive up to an additional USD 2.967 billion (approximately USD 3.02 billion) in milestone payments tied to clinical development, regulatory approval and commercialization. The maximum combined deal value is USD 3.054 billion (approximately USD 3.11 billion), with separate tiered royalties linked to sales if the resulting treatments reach the market. Eli Lilly will secure exclusive worldwide rights to some development programs, and exclusive rights outside mainland China, Hong Kong, Macao and Taiwan for the remaining programs.

Table 1. Eli Lilly's Investments and Partnerships in China

AreaPartnerKey DetailsInvestment / Deal Value
Drug delivery technologyMETiS TechBioJoint development of tissue-specific LNP delivery technology using an AI platformTens of millions of USD upfront, up to USD 1.1 billion in milestone payments, and tiered royalties at single-digit percentages
Manufacturing and supply chainPharmaron and othersUpgrading Suzhou manufacturing facilities, expanding oral solid dosage manufacturing capacity in Beijing, and establishing a local supply chain for orforglipronUSD 3 billion investment over the next 10 years, with USD 200 million allocated to the Pharmaron partnership
Joint drug developmentHaisco PharmaceuticalHaisco to handle candidate discovery and early-stage research for up to 5 targets selected by Eli LillyUp to USD 87 million in upfront and near-term payments, up to USD 2.967 billion in milestone payments, and tiered royalties
Source: Compiled from foreign media reports

Global Big Pharma Looks to China for New Drugs

Beyond Eli Lilly, numerous global Big Pharma companies are looking to China to fill gaps in their existing pipelines. According to Deloitte China, the Chinese arm of global accounting and consulting firm Deloitte, out-licensing deals involving innovative Chinese drugs totaled USD 99.7 billion (approximately USD 102 billion) in the first half of this year, nearly double the full-year 2024 figure of USD 52 billion (approximately USD 53.0 billion). A recent string of major deals between global Big Pharma and Chinese companies within a short period has also drawn market attention. From the 28th of last month through the 2nd of this month, agreements signed by U.S.-based Merck (MSD), Denmark's Novo Nordisk and Switzerland's Novartis with Chinese pharmaceutical companies had a combined maximum value of USD 12.53 billion (approximately USD 12.8 billion), with upfront payments alone totaling USD 1.275 billion (approximately USD 1.30 billion).

Against this backdrop, upfront payments for Chinese pharmaceutical and biotech companies' out-licensing deals are also rising. Data from global market research firm Evaluate show that the average upfront payment in deals between global Big Pharma and Chinese biotech companies increased by approximately 231%, from USD 52 million (approximately USD 53.1 million) in 2022 to USD 172 million (approximately USD 175 million) this year. JPMorgan also found that Chinese companies' drug candidates accounted for 50% of major global pharmaceutical companies' in-licensing deals with upfront payments of at least USD 50 million (approximately USD 50.8 million) in the first quarter of this year, up from 5% in 2021, measured by the number of transactions.

Chinese Government Steps Up Support

Meanwhile, the Chinese government is strengthening policy support to sustain growth in its pharmaceutical and biotech industries. A prominent example is the joint release last month of the 15th Five-Year Plan for Pharmaceutical Industry Development, covering 2026–2030, by 10 government bodies, including China's Ministry of Industry and Information Technology, the National Development and Reform Commission, and the National Medical Products Administration. The plan aims to raise China's share of first-in-class (FIC) drugs—the first worldwide to use a new target or mechanism of action—to at least 25% by 2030, and to have at least 5 medicines with annual global sales exceeding USD 1 billion (approximately USD 1.02 billion). It also seeks to expand the innovative drug industry by an annual average of at least 20%.

China also plans to advance its approach to partnerships with overseas pharmaceutical companies. Previously, these relationships centered on out-licensing deals through which Chinese companies transferred overseas development and marketing rights for internally developed drug candidates to global pharmaceutical companies. Going forward, the aim is to participate in joint R&D from the drug discovery stage and broaden collaboration to include overseas clinical trials and commercialization. Increased R&D investment and institutional improvements will proceed in parallel. The Chinese government has set goals of raising listed pharmaceutical companies' average annual R&D investment to at least 10% of revenue and, by 2030, fostering 50 pharmaceutical companies with annual revenue of at least CNY 10 billion (approximately USD 1.53 billion) and 20 pharmaceutical industrial parks with annual industrial output of at least CNY 100 billion (approximately USD 15.3 billion). It will also improve drug review and approval procedures and refine policies on drug pricing, medical insurance reimbursement and clinical use to help translate R&D achievements into product launches and sales.

Picture

Member for

2 years
Real name
Tyler Hansbrough
Bio
[email protected]

As one of the youngest members of the team, Tyler Hansbrough is a rising star in financial journalism. His fresh perspective and analytical approach bring a modern edge to business reporting. Whether he’s covering stock market trends or dissecting corporate earnings, his sharp insights resonate with the new generation of investors.